Physician profile
John A Balacko
NPI 1942269311
$4,383.69
in general payments reported to CMS, 2019-2025
35 companies · $523 in 2025
The $523 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $191 · 2021: $243 · 2022: $521 · 2023: $1,389 · 2024: $814 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $681.13 | 2019-2025 | |
| Amgen INC. | $627.50 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $487.75 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $414.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $341.03 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $273.07 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $186.62 | 2019-2024 | Camzyos, Eliquis |
| Heartflow, INC. | $184.14 | 2023-2024 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $157.52 | 2019-2025 | Farxiga, Wainua |
| Abiomed | $137.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.86 | 2019-2024 | Jardiance |
| Shockwave Medical, INC | $86.80 | 2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Actelion Pharmaceuticals US, INC. | $83.72 | 2019 | |
| Kestra Medical Technology Services, INC. | $59.20 | 2024 | Assure Wcd |
| Boston Scientific Corporation | $50.52 | 2019-2023 | Watchman Access System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.01 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $45.39 | 2023-2024 | Onpattro |
| Tactile Systems Technology INC | $43.08 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Kiniksa Pharmaceuticals International, Plc | $41.87 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $39.43 | 2023 | |
| Chiesi USA, INC. | $38.80 | 2020-2023 | Kengreal |
| Novo Nordisk INC | $31.19 | 2025 | Wegovy |
| Angiodynamics, INC. | $26.82 | 2020 | |
| Merck Sharp & Dohme LLC | $24.85 | 2025 | Winrevair |
| Daiichi Sankyo INC. | $23.40 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals, LTD. | $22.09 | 2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $18.85 | 2023 | Definity |
| Astellas Pharma US INC | $18.59 | 2023 | Lexiscan |
| Biotronik INC. | $17.46 | 2020 | |
| Amarin Pharma, INC. | $16.26 | 2021 | |
| Irhythm Technologies, INC. | $14.34 | 2024 | Zio Xt Patch, Zio Monitor |
| Bracco Diagnostics INC. | $14.00 | 2021 | |
| Gilead Sciences, INC. | $11.24 | 2019 | |
| Cardiovascular Systems INC. | $3.81 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Balacko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.